India Expected To Have Surplus Vaccines In 6 Months

New Delhi: The chief architect of Aadhaar and co-founder of Infosys, Nandan Nilekani, on Friday said that India is most likely to see a surplus in vaccine production in the next 6 months.

Currently, Serum Institute of India (SII) and Bharat Biotech are manufacturing COVID-19 vaccines.

Speaking an event, Nilekani said that vaccination efforts can be further scaled up with the help of the Covid Vaccine Intelligence Network (CoWIN) platform, along with private partnerships, in the future.

“India will be a role model in providing vaccination at scale with agility. It is also one of the first countries to create and digitise a vaccine certification process, which will help the Indian population considerably,” said Nilekani.

“The vaccination process should be registered. The government is doing a great job to create digital certificates after vaccination and equipping them with QR. Through this, the Indian populace can now carry these certificates on their smartphone or DigiLockers and the QR can be easily scanned in transit points like airports,” he added.

He also said that once ample vaccines are available in both the private and government sector, vaccination can be scaled up considerably.

India started the vaccination process on January 16 and aims to vaccinate 30 million healthcare and frontline workers by March. More than 1.04 million people have already received the jab in the country.